Dystrophin: From non-ischemic cardiomyopathy to ischemic cardiomyopathy

Medical Hypotheses

Volumn 71, Issue 3, 2008, Pages 434-438

  Zheng, Qiang Sun ^a   Guo, Wan Gang ^a   Lu, Zi Fan ^b   Shi, Xiao Qin ^c   Su, Fei Fei ^a   Li, Hua ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN;

ARTICLE; CARDIOMYOPATHY; GENE MUTATION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE;

CARDIOMYOPATHIES; DYSTROPHIN; GLYCOPROTEINS; HUMANS; MYOCARDIAL ISCHEMIA; VENTRICULAR REMODELING;

EID: 47549086497     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.04.004     Document Type: Article

References (26)

1. Lapidos K.A., Kakkar R., and McNally E.M. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res 94 (2004) 1023-1031
2. Kaprielian R.R., Stevenson S., Rothery S.M., Cullen M.J., and Severs N.J. Distinct patterns of dystrophin organization in myocyte sarcolemma and transverse tubules of normal and diseased human myocardium. Circulation 101 (2000) 2586-2594
3. Feener C.A., Koenig M., and Kunkel L.M. Alternative splicing of human dystrophin mRNA generates isoforms at the carboxy terminus. Nature 338 (1989) 509-511
4. Kamogawa Y., Biro S., Maeda M., et al. Dystrophin-deficient myocardium is vulnerable to pressure overload in vivo. Cardiovasc Res 50 (2001) 509-515
5. Mestroni L., Rocco C., Gregori D., et al. Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart muscle disease study group. J Am Coll Cardiol 34 (1999) 181-190
6. Acsadi G., Lochmuller H., Jani A., et al. Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. Hum Gene Ther 7 (1996) 129-140
7. Goodwin F.C., and Muntoni F. Cardiac involvement in muscular dystrophies: molecular mechanisms. Muscle Nerve 32 (2005) 577-588
8. Ikeda Y., Martone M., Gu Y., et al. Altered membrane proteins and permeability correlate with cardiac dysfunction in cardiomyopathic hamsters. Am J Physiol Heart Circ Physiol 278 (2000) H1362-H1370
9. Kimura S., Ikezawa M., Ozasa S., et al. Novel mutation in splicing donor of dystrophin gene first exon in a patient with dilated cardiomyopathy but no clinical signs of skeletal myopathy. J Child Neurol 22 (2007) 901-906
10. Danialou G., Comtois A.S., Dudley R., et al. Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J 15 (2001) 1655-1657
11. Khairallah M., Khairallah R., Young M.E., Dyck J.R., Petrof B.J., and Des Rosiers C. Metabolic and signaling alterations in dystrophin-deficient hearts precede overt cardiomyopathy. J Mol Cell Cardiol 43 (2007) 119-129
12. Pagel C.N., and Morgan J.E. Myoblast transfer and gene therapy in muscular dystrophies. Microsc Res Tech 30 (1995) 469-479
13. Goncalves M.A., van Nierop G.P., Tijssen M.R., et al. Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability. J Virol 79 (2005) 3146-3162
14. Athanasopoulos T., Graham I.R., Foster H., and Dickson G. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). Gene Ther 11 Suppl. 1 (2004) S109-S121
15. Townsend D., Blankinship M.J., Allen J.M., Gregorevic P., Chamberlain J.S., and Metzger J.M. Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol Ther 15 (2007) 1086-1092
16. Yue Y., Li Z., Harper S.Q., Davisson R.L., Chamberlain J.S., and Duan D. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 108 (2003) 1626-1632
17. Allamand V., and Campbell K.P. Animal models for muscular dystrophy: valuable tools for the development of therapies. Hum Mol Genet 9 (2000) 2459-2467
18. Lee G.H., Badorff C., and Knowlton K.U. Dissociation of sarcoglycans and the dystrophin carboxyl terminus from the sarcolemma in enteroviral cardiomyopathy. Circ Res 87 (2000) 489-495
19. Badorff C., Lee G.H., Lamphear B.J., et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 5 (1999) 320-326
20. Chopra V. Enteroviruses prefer the dystrophin-deficient heart. Clin Genet 62 (2002) 370-372
21. Henry L.B. Left ventricular systolic dysfunction and ischemic cardiomyopathy. Crit Care Nurs Q 26 (2003) 16-21
22. Schinkel A.F., Poldermans D., Rizzello V., et al. Why do patients with ischemic cardiomyopathy and a substantial amount of viable myocardium not always recover in function after revascularization?. J Thorac Cardiovasc Surg 127 (2004) 385-390
23. Kyoi S., Otani H., Hamano A., et al. Dystrophin is a possible end-target of ischemic preconditioning against cardiomyocyte oncosis during the early phase of reperfusion. Cardiovasc Res 70 (2006) 354-363
24. Rodriguez M., Cai W.J., Kostin S., Lucchesi B.R., and Schaper J. Ischemia depletes dystrophin and inhibits protein synthesis in the canine heart: mechanisms of myocardial ischemic injury. J Mol Cell Cardiol 38 (2005) 723-733
25. Armstrong S.C., Latham C.A., Shivell C.L., and Ganote C.E. Ischemic loss of sarcolemmal dystrophin and spectrin: correlation with myocardial injury. J Mol Cell Cardiol 33 (2001) 1165-1179
26. Kido M., Otani H., Kyoi S., et al. Ischemic preconditioning-mediated restoration of membrane dystrophin during reperfusion correlates with protection against contraction-induced myocardial injury. Am J Physiol Heart Circ Physiol 287 (2004) H81-H90